HER-2 positive and p53 negative breast cancers are associated with poor prognosis.
AffiliationDepartment of Surgery, Beaumont Hospital, Dublin, Ireland. email@example.com
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Proportional Hazards Models
Tumor Markers, Biological/*analysis
Tumor Suppressor Protein p53/*analysis
MetadataShow full item record
CitationCancer Invest. 2011 Jun;29(5):365-9.
Abstractp53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02) . p53 expression relates to HER-2 expression (p = .029). Coexpression between p53 and HER-2 has no relation to prognosis. On univariate and multivariate analysis, combination of HER-2 positive and p53 negative expression was associated with a poor prognosis (p = .018 and p = .027, respectively), while the combination of HER-2 negative and p53 positive expression was associated with a favorable prognosis (p = .022 and p = .010, respectively). Therefore the expression of these markers should be considered collectively.
- Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
- Authors: Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS
- Issue date: 2004 Feb 1
- Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
- Authors: Ren J, Chen QC, Jin F, Wu HZ, He M, Zhao L, Yu ZJ, Yao WF, Mi XY, Wang EH, Wei MJ
- Issue date: 2014
- Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
- Authors: Yu H, Levesque MA, Clark GM, Diamandis EP
- Issue date: 1999 Oct
- Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
- Authors: Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ
- Issue date: 2007 Apr 12
- Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.
- Authors: Lee DS, Kim SH, Suh YJ, Kim S, Kim HK, Shim BY
- Issue date: 2011 Jul